Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents and Young Adults With Treatment Refractory Cancer

Trial Profile

A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents and Young Adults With Treatment Refractory Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Clear cell sarcoma; Malignant melanoma; Osteosarcoma; Sarcoma; Solid tumours; Synovial sarcoma
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 22 Jan 2018 According to a Bristol-Myers Squibb media release, the European Commission (EC) has expanded the indication of Yervoy (ipilimumab) to include treatment of advanced (unresectable or metastatic) melanoma in pediatric patients 12 years of age and older.
    • 03 Nov 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 24 Jan 2012 Planned number of patients changed from 38 to 34 as reported by ClinicalTrials.gov (NCT01445379).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top